Compare TDW & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TDW | SYRE |
|---|---|---|
| Founded | 1956 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.6B |
| IPO Year | N/A | 2016 |
| Metric | TDW | SYRE |
|---|---|---|
| Price | $52.92 | $31.02 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $67.50 | $56.50 |
| AVG Volume (30 Days) | 623.9K | ★ 850.2K |
| Earning Date | 02-26-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.97 | N/A |
| Revenue | ★ $1,361,073,000.00 | N/A |
| Revenue This Year | $0.76 | N/A |
| Revenue Next Year | $0.81 | N/A |
| P/E Ratio | $17.95 | ★ N/A |
| Revenue Growth | ★ 4.42 | N/A |
| 52 Week Low | $31.17 | $10.91 |
| 52 Week High | $64.07 | $35.31 |
| Indicator | TDW | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 50.09 | 49.54 |
| Support Level | $49.92 | $28.00 |
| Resistance Level | $55.07 | $33.31 |
| Average True Range (ATR) | 1.75 | 1.54 |
| MACD | 0.14 | -0.68 |
| Stochastic Oscillator | 61.12 | 44.15 |
Tidewater Inc provides marine and transportation services to the offshore energy industry. The company's vessels and associated services support all phases of offshore crude oil and natural gas (also referred to as oil and gas) exploration activities, field development, production, and maintenance, as well as windfarm development and maintenance. Its services include towing and anchor handling for mobile offshore drilling units; transporting supplies and personnel necessary to sustain drilling, workovers, production activities, field abandonment, dismantlement, and restoration activities; and Others. The group manages its business through five segments including the Americas, Asia Pacific, Middle East, Europe/Mediterranean, and West Africa.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.